Healthcare Private Placement and M&A Transactions Review Week Ending December 17, 2023

Tome Biosciences: The company raised $117.5 million of Series B venture funding from GV, Bruker and Fujifilm Healthcare on December 12, 2023, putting the company’s pre-money valuation at $300 million. Alexandria Venture Investments and 4 other investors also participated in the round. The company is an operator of a biotechnology company intended to offer programmable gene insertion technology.

Synnovation Therapeutics: The company raised $69.8 million of venture funding from undisclosed investors on December 14, 2023. The company is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.

Totus Medicines: The company raised $66 million of venture funding in a deal led by DCVC Bio on December 15, 2023. Northpond Ventures and Camford Capital also participated in the round. The company is a developer of chemical biology technologies designed to treat mutated oncogenes.

Deep Apple: The company raised $52 million of Series A venture funding from Apple Tree Partners (ATP) on December 14, 2023. The company focuses on combining capabilities in molecular docking and structural biology through advanced computer-aided drug design technologies

Shinobi Therapeutics: The company raised $51 million through a combination of debt and Series A venture funding in a deal led by Eight Roads, EQT Life Sciences and F-Prime Capital on December 12, 2023, putting the company’s pre-money valuation at $64 million. Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments, D3 (Tokyo) and Kyoto University Innovation Capital also participated in the round. The company is a developer of cell therapies intended for comprehensive immune evasion.

Parse Biosciences: The company raised $50 million of Series C venture funding through a combination of equity and debt on December 14, 2023. The equity part of the deal was led by Soleus Capital. Bioeconomy Capital, Sahsen Ventures, Marshall Wace, Janus Henderson Investors, and Saras Capital also participated in the round. The company is a developer of a single-cell sequencing technology designed to perform experiments without the need for custom instrumentation.

Laza Medical: The company raised $36 million of Series A venture funding in a deal led by The Capital Partnership on December 12, 2023. PA MedTech VC Fund, GE Healthcare, Unorthodox Ventures, Shifamed and Dara Holdings also participated in the round. The company is an operator of a medical device development company intended to provide AI-powered robotically-assisted imaging for cardiovascular interventions.

Zafrens: The company raised $23 million of venture funding in a deal led by Prime Movers Lab on December 11, 2023. KOFA Healthcare, Global Brain, Alix Ventures, BlueYard Capital, Hawktail, FoundersX Ventures, Iaso Ventures, Possible Ventures and other undisclosed investors also participated in the round. The company is developing an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day.

Encellin: The company raised $9.9 million of Series A venture funding in a deal led by Khosla Ventures on December 13, 2023, putting the company’s pre-money valuation at $35 million. Evolution VC Partners, SVLC, Formic Ventures, Ascendant Venture, California Innovation Fund, Pier 70 Ventures, Y Combinator and Sand Hill Angels also participated in the round. The company is an operator of a biotechnology company intended to develop a novel thin-film cell encapsulation device for cell-based therapeutics.

Reprise Biomedical: The company raised $8 million of venture funding from undisclosed investors on December 13, 2023. The company is a developer of biological medical products designed to support cellular integration.

Samabriva: The company received EUR 4 million of development capital from Noshaq, Investsud and other undisclosed investors on December 12, 2023. The company is a developer of protein-based pathogens for producing biopharmaceuticals, chemicals, and biotechnology.

PanTher Therapeutics: The company raised $3.9 million of venture funding in the form of convertible debt from undisclosed investors on December 15, 2023. The company engineers customized therapeutic solutions to address the specific challenges dictated by tumor type, location, and therapeutic regime.

Irazu Oncology: The company raised $2.6 million of venture funding in the form of convertible debt from undisclosed investors on December 14, 2023. The company is a developer of a vaccine platform designed to improve clinical outcomes for cancer patients.

EsoBiotec: The company closed on EUR 2 million of an undisclosed targeted amount of Series A venture funding from UCB Ventures, Wallonie Entreprendre and Thuja Capital Management on December 12, 2023. SambrInvest also participated in the round. The company is a developer of in vivo engineering for cancer fighting immunotherapies.

Seagen / Pfizer: The company was acquired by Pfizer for $43 billion on December 15, 2023. Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers.

Icosavax / AstraZeneca: The company reached a definitive agreement to be acquired by AstraZeneca for $1.1 billion on December 11, 2023. Icosavax Inc is a biopharmaceutical company that develops safe and effective vaccines against infectious diseases and respiratory viruses.

Miromatrix Medical / United Therapeutics: The company was acquired by United Therapeutics for $140 million (including potential earn-out) on December 11, 2023. Miromatrix Medical Inc is a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives.

Applied BioMath / Certara: The company was acquired by Certara for an undisclosed amount on December 14, 2023. The company is a developer of a mathematical modeling and simulation platform designed to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies.

Kamata / Sunsho Pharmaceutical: The company was acquired by Sunsho Pharmaceutical, a subsidiary of TOWA Pharmaceutical Company, for an undisclosed amount on December 11, 2023. The company is a manufacturer of capsules, tablets and granules for the healthcare industry.

KriGen Pharmaceuticals / DifGen Pharmaceuticals: The company reached a definitive agreement to be acquired by DifGen Pharmaceuticals for an undisclosed amount on December 11, 2023. The company is a research oriented pharmaceutical company focused on the development of various novel dosage forms.

Rain Oncology / Pathos: The company reached a definitive agreement to be acquired by Pathos for an undisclosed amount on December 13, 2023. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit.

Strateos / Programisto: The company was acquired by Programisto for an undisclosed amount on December 11, 2023. The company is a developer of remote access laboratories and lab control software for life science discovery.

TuHURA Biosciences / CohBar: The company acquired CohBar through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol HURA on December 14, 2023. TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies.